Get the Daily Brief
Latest Biotech News
FDA approval – hearing loss gene therapy hits first-in-class milestone
The U.S. FDA has approved Regeneron’s Otarmeni (lunsotogene parvec), an AAV-mediated gene therapy for hearing loss caused by otoferlin (OTOF) variants, clearing the first gene therapy under the...
Regulators and payers – FDA/CMS RAPID aims to shorten device coverage after breakthrough designation
The U.S. FDA and the Centers for Medicare & Medicaid Services (CMS) announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway to speed Medicare coverage for...
Precision oncology – AI-microscopy platform aims to quantify single-cell breast cancer risk
City of Hope and UC Berkeley researchers unveiled a microfluidic platform to analyze single breast cells under mechanical stress, aiming to detect cancer risk at the cellular level. The approach,...
Oncology therapeutics – new targeted ADC data in platinum-resistant ovarian cancer
A Phase I study presented at AACR 2026 reported clinical benefit from QLS5132, an investigational antibody-drug conjugate targeting CLDN6 in patients with advanced platinum-resistant ovarian...
Cancer genomics – HOST-Factor tool quantifies radiation effects on pancreatic tumor stroma
Fox Chase Cancer Center researchers introduced HOST-Factor, a quantitative scoring tool intended to characterize how radiation reprograms the pancreatic tumor microenvironment. The platform...
Infectious disease AI – SyntheMol-RL designed a new antibiotic in preliminary tests
McMaster University researchers reported a generative AI model, SyntheMol-RL, that accelerates antimicrobial discovery and in early work generated a candidate antibiotic. The study frames the...
Cell therapy – KIR-CAR T aims to reduce exhaustion in solid tumors
Researchers at the University of Pennsylvania presented first-in-human Phase I data on SynKIR-110, a “KIR-CAR” T cell therapy designed to address exhaustion seen in conventional CAR T approaches...
Rare disease clinical development – prion siRNA enters first human trial
A phase 1 clinical trial has started for a divalent siRNA candidate targeting prion disease, marking the first human testing of the molecule described as a novel approach for the fatal...
Biotech funding and infrastructure – Alloy Therapeutics raises Series E to scale tech-enabled platform
Alloy Therapeutics raised $40 million in a late-stage Series E to expand its tech-enabled biotech infrastructure. The company said it will use the funding to strengthen its discovery engine, push...
Manufacturing investment – AbbVie’s $1.4B Durham campus targets sterile injectable capacity
AbbVie announced a $1.4 billion manufacturing investment in Durham, North Carolina, building an approximately 185-acre campus near Research Triangle Park. The project aims to expand production...
FDA approvals / gene therapy
The FDA cleared Regeneron’s gene therapy Otarmeni for a rare inherited hearing loss condition, marking the first gene therapy greenlit under the agency’s National Priority Voucher program....
Regulatory pathway for devices (Medicare coverage speed)
The FDA and CMS announced the RAPID coverage pathway to cut the time between FDA breakthrough medical device authorization and Medicare national coverage. Under RAPID, CMS will issue a proposed...
Drug pricing and voucher-driven policy signals
President Trump’s administration marked a policy milestone on drug pricing deals while Regeneron simultaneously announced a related gene therapy approval. The administration said it closed a first...
Oncology: pancreatic cancer expands first-line RAS strategy
Revolution Medicines brought new updated data for daraxonrasib into the first-line pancreatic cancer discussion at AACR, extending the company’s already strong momentum around RAS(ON) inhibition....
Oncology: next-wave ADCs in ovarian cancer
QLS5132, an investigational CLDN6-targeting antibody-drug conjugate, showed clinical benefit in patients with heavily pretreated platinum-resistant ovarian cancer in a Phase I study presented at...
Oncology: ADC activity in KRAS G12D NSCLC
Early clinical data on zoldonrasib at AACR 2026 highlighted objective responses in previously treated KRAS G12D–mutant non-small cell lung cancer, a subgroup lacking approved RAS-directed options....
Cell & gene therapy: lentiviral manufacturing strategies for in vivo delivery
SK pharmteco highlighted manufacturing best practices aimed at enabling in vivo lentiviral therapies, focusing on purity, scalability, and clinical readiness. In a GEN Podcast, SK pharmteco...
CRISPR and gene editing: base editing corrects ‘untreatable’ CFTR splice mutation
A new Science Translational Medicine report described base-editing approaches that functionally correct the CFTR 1717-1G>A splicing mutation in patient-derived cell models. The target mutation is...
Company / biotech financing and capital markets
Lucid Diagnostics priced an underwritten registered direct offering of 18 million common shares at $1.00 per share, raising $18 million gross proceeds. The financing is anchored by a $15 million...
Genetic risk tools and cancer predisposition management
MD Anderson researchers validated LFSPRO, a mathematical model designed to improve identification of individuals at elevated risk for Li-Fraumeni syndrome by integrating genetic and clinical risk...